Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice

Br J Dermatol. 2022 Apr;186(4):733-735. doi: 10.1111/bjd.20883. Epub 2022 Jan 20.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab